NHL Charts, page-937

The Company intends to provide further guidance on the deployment and billing schedule for TALi Detect in the near future as it works with physicians and customers in the U.S. during initial launch. As stated, it will also provide guidance on any potential reimbursement for TALi Train as appropriate.

The Company also plans to provide a completion update in relation to the CRC-P ( “Project ” that has developed TALi Detect in conjunction with our partners along with outlining the clinical trial data from that project.

They just raised $2m last month.

This is directly quoted from the Annual Report released last Thursday:
On Page 5,
"The ability of the Group to meet operating cash requirements for the next 12 months has been secured by an Entitlement Offer to shareholders raising a total of $2.0 million (as announced to ASX on 19 September 2019) which will be added to the existing cash on hand of $0.3 million at the year end. Beyond the next 12 months, the Group expects cash flows being generated from the successful execution of the TALi commercialisation strategy and development opportunities will support the cash position of the Company. "